Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLD) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96.
Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 2013;53:427-36.
Diamond M, Cady R. Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care. Am J Med 2005;118:18S-27S.
Gupta MX, Silberstein SD, Young WB, et al. Less is not more: underutilization of headache medications in a university hospital emergency department. Headache 2007;47: 1125-33.
Friedman BW, Bijur PE, Lipton RB. Standardizing emer- gency department-based migraine research: an analysis of commonly used clinical trial outcome measures. Acad Emerg Med 2010;17:72-9.
Dodick DW. Clinical clues and clinical rules: primary versus secondary headache. Adv. Stud Med 2003;3:550-5.
Headache Classification Committee of the International Headache Society (IHS).The International Classification of Headache Disorders, 3rd edition (beta version). Cepha- lalgia 2013;33:629-808.
Lipton RB, Dodick D, Sadovsky R, et al. A self-adminis- tered screener for migraine in primary care: the ID Migraine™ validation study. Neurology 2003;61:375-82.
Mostardini C, d’Agostino VC, Dugoni DE, et al. A pos- sible role of ID-Migraine in the emergency department: study of an emergency department out-patient population. Cephalalgia 2009;29:1326-30.
Cousins G, Hijazze S, Van de Laar FA, et al. Diagnostic accuracy of the ID Migraine: a systematic review and meta-analysis. Headache 2011;51:1140-8.
Silberstein SD. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache 1995; 35:387-96.
Silberstein S. Gastrointestinal manifestations of migraine: meeting the treatment challenges. Headache 2013;53:1-3
Logan P, Lewis D. Chlorpromazine in migraine. Emerg Med J 2007;24:297-300.
Shrestha M, Singh R, Moreden J, et al. Ketorolac vs. chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern Med 1996;156:1725-8.
Barbanti P, Fofi L, Aurilia C, et al. Dopaminergic symp-toms in migraine. Neurol Sci 2013;34:S67-70.
Ghosh J, Pradhan S, Mittal B. Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility. Neuromolecular Med 2013;15:61-73.
Todt U, Netzer C, Toliat M, et al. New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet 2009; 125:265-79.
Castillo J, Martinez F, Suarez C, et al. Cerebrospinal fluid tyrosine and 3,4-dihydroxyphenyl-acetic acid levels in migraine patients. Cephalalgia 1996;16:56-61.
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache 2012;52:292-306.
Marmura J. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 2012;14:27-35.
Kelly AM, Walcynski T, Gunn B. The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis. Headache 2009;49:1324-32.
Bigal ME, Bordini CA, Speciali JG. Intravenous chlor- promazine in the emergency department treatment of migraine: A randomized controlled trial. J Emerg Med 2002;23:141-8.
Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhy- drinate in migraine headache. Ann Emerg Med 1989;18 360-5.:
Bell R, Montoya D, Shuaib A, et al. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med 1990;19:1079-82.
Kelly AM, Ardagh M, Curry C, et al. Intravenous chlor- promazine vs. intramuscular sumatriptan for acute migraine. J Accid Emerg Med 1997;14:209-11.
Colman I, Brown MD, Innes GD, et al. Parenteral meto- clopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ 2004;329:1369-73.
Tek DS, McClellan DS, Olshaker JS, et al. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med 1990;19:1083-7.
Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995;26:541-6.
Tfelt-Hansen P, Olesen J, Aebelholt-Krabbe A, et al. A double blind study of metoclopramide in the treatment of migraine attacks. J Neurol Neurosurg PsyChiatry 1980;43: 369-71.
Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993;22:191-5.
Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Am J Emerg Med 1996;14:262-4.
Cameron JD, Lane PL, Speechley M. Intravenous chlor- promazine vs. intravenous metoclopramide in acute migraine headache. Acad Emerg Med 1995;2:597-602.
Cete Y, Dora B, Ertan C, et al. A randomized perspective placebo-controlled study of intravenous magnesium sulfate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia 2004;25:199-204.
Friedman BW, Corbo J, Lipton RB, et al. A trial of meto- clopramide vs. sumatriptan for the emergency department treatment of migraines. Neurology 2005;64:463-8.
Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med 2011;57:475-82.
Honkaniemi J, Liimatainen S, Rainesalo S, et al. Halo- peridol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache 2006; 46:781-7.
Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001;53: 167-78.
Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997;53: 139-88.
Strom BL, Berlin lA, Kinman JL, et al. Parenteral ketoro- lac and risk of gastrointestinal and operative site bleeding: a post marketing surveillance study. JAMA 1996;275: 376-82.
DuBose lr TO, Molony DA, Verani R, et al. Nephrotoxicity of non-steroidal anti-inflammatory drugs. Lancet 1994; 344:515-8.
Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med 2002;39:215-222.
Taggart E, Doran S, Kokotillo A, et al. Ketorolac in the treatment of acute migraine: a systematic review. Head- ache 2013;53:277-87.
Colman I, Rothney A, Wright S, et al. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 2004;62:1695-700.
Meredith JT, Wait S, Brewer KL. A prospective double- blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med 2003;21:173-5.
Seim MB, March JA, Dunn KA. Intravenous ketorolac vs. intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med 1998;5:573-6.
Shrestha M, Singh R, Moreden J, et al. Ketorolac vs. chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch Intern Med 1996;156:1725-8.
Schuh-Hofer S, Tayefeh M, Reuter U, et al. Effects of parecoxib on plasma protein extravasation and c-fos expression in the rat. Headache 2006;46:276-85.
Müller T, Lohse L. Efficacy of parecoxib, sumatriptan, and rizatriptan in the treatment of acute migraine attacks. Clin Neuropharmacol 2011;34:206-9.
Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med 2002;39:215-22.
Colman I, Rothney A, Wright SC, et al. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 2004;62:1695-700.
Levin M. Opioids in Headache. Headache 2014;54:12-21.
Buse DC, Pearlman SH, Reed ML, et al. Opioid use and dependence among persons with migraine: results of the AMPP study. Headache 2012;52:18-36.
Bigal ME, Lipton RB. Excessive opioid use and the devel- opment of chronic migraine. Pain 2009;142:179-82.
Bigal ME, Serrano D, Buse D, et al. Acute migraine medi- cations and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48:1157-68.
Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical consider- ations. Clin J Pain 2008;24:479-96.
Tepper SJ. Opioids should not be used in migraine. Head- ache 2012;52:30-4.
Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache 2009;49:395-403.
Friedman BW, Hochberg ML, Esses D, et al. Recurrence of primary headache disorders after emergency depart- ment discharge: Frequency and predictors of poor pain and functional outcomes. Ann Emerg Med 2008;52: 696-704.
Friedman BW, Kapoor A, Friedman MS, et al. The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials. Ann Emerg Med 2008;52:705-13.
Tepper DE, Kelley NE. Rescue therapy for acute migraine, part 3: Opioids, NSAIDs, steroids, and post- discharge medications. Headache 2012;52:467-82.
Finocchi C, Viani E. Opioids can be useful in the treat-ment of headache. Neurol Sci 2013;34:S119-24.
Alemdar M, Pekdemir M, Selekler HM. Single-dose intravenous tramadol for acute migraine pain in adults: A single-blind, prospective, randomized, placebo-controlled clinical trial. Clin Ther 2007;29:1441-7.
Engindeniz Z, Demircan C, Karli N, et al. Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: A prospective, randomized, double-blind study. J Headache Pain 2005;6: 143-8.